Canaccord Genuity Starts BioNTech (BNTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $90.70 +4.35%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee initiates coverage on BioNTech (NASDAQ: BNTX) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.
Shares of BioNTech closed at $17.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech (BNTX) PT Lowered to $106 at Morgan Stanley
- BMO Capital Starts Astera Labs (ALAB) at Outperform
- BioNTech (BNTX) PT Lowered to $108 at BofA Securities
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
